Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78

Benzinga · 2d ago
Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $80 to $78.